Dépistage de la trisomie 21 au premier trimestre. Bilan de 6 années à Prima facie

Conclusions Le dépistage de la trisomie 21 par le calcul du risque combiné du 1er trimestre a permis de dépister 86,7 % des trisomies 21 avec un taux de faux-positifs de 5,6 %. Objective To evaluate the results of screening for trisomy 21 by the combined risk of first trimester (as defined by the decree of June 23, 2009) in the Prima facie structure. Methods Single center study involving all patients that were seen for first trimester screening at Prima facie with singleton living pregnancy, not obtained by embryo donation, between 1 January 2009 and 31 December 2014. Results Eighteen thousand two hundred and fifty-one patients were included, of which underwent screening for trisomy 21 by the combined risk. One thousand and forty-six (6.1%) had a calculated risk higher than 1/250. Seventy-five were affected by trisomy 21, of whom 65 in the high risk group. The sensitivity and specificity of screening are 86.7% and 94.4%. The median nuchal translucency was 0.98 MoM. Conclusions Screening for trisomy 21 by calculating the combined risk of first trimester enabled to detect 86.7% of trisomy 21 with a false positive rate of 5.6%.

Source: Gynecologie Obstetrique and Fertilite - December 23, 2015 Category: OBGYN Source Type: research